PARSIPPANY, N.J., Nov. 30, 2016 /PRNewswire/ -- Kline, a global market research and management consulting firm, and Promotum, a management consulting firm specializing in business development at the convergence of fuels, chemicals, and biologics, announce a series of reports analyzing the impact of synthetic biology on the specialty chemical and allied industries. The first report, Synthetic Biology: Opportunities and Threats for Renewables in Personal Care, will focus on personal care ingredients and describe the future of emollients, packaging, antimicrobials, and other segments. In addition, it will provide an analysis of key players, such as Intrexon, the Life Sciences group of REG, Ginkgo BioWorks, and Zymergen.
A revolution in how personal care ingredients are sourced and synthesized is now under way. Driven by consumer preference for more natural products, ingredients made via synthetic biology will increasingly replace those made by synthetic chemistry.
Rare, expensive, labor-intensive, or politically sensitive ingredients previously made from petroleum or extracted at low concentrations from animal or plant sources can now be cultured like wine and cheese without incurring the wrath of PETA, humanitarian, or environmental groups.
Micro-organisms effectively convert feedstock to product in a single step, but their chemical intermediates are very different from those in a petrochemical refinery, and those intermediates can cut across traditional silos far beyond chemicals. A single biological pathway may yield pharmaceuticals, emollients, and fuels.
"More than new biology, this revolution is a collision of genetics, information science, and robotics," says Sam Nejame, CEO of Promotum, co-author of the upcoming report.
"Today, we may be in the chemical industry, but in the future, we will be in the sustainable functionalized carbon industry," Nejame adds.
Synthetic biology will impact everything from space exploration, flavors and fragrances, food, agriculture, pharmaceuticals, and nutriceuticals to personal care and every heavy industry in-between, but not every synthetic biology company will be successful.
Sam Nejame is CEO of Promotum. For more than 25 years, he has provided market analysis, business development, consulting, and engineering services to Fortune 500 Companies, start-ups, and investors. His practice focuses on issues of sustainability and technology commercialization. He has consulted extensively within the biotechnology, chemicals, and fuels industries.
Kline is a worldwide consulting and research firm dedicated to providing the kind of insight and knowledge that helps companies find a clear path to success. The firm has served the management consulting and market research needs of organizations in the agrochemicals, chemicals, materials, energy, life sciences, and consumer products industries for over 50 years. For more information, visit www.KlineGroup.com.
For more information contact: Vera Sandarova Marketing Communications [email protected]